SURF Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 Sep 2023 @ 16:00):

Stats
Today's Volume	1.46M
Average Volume	798 146
Market Cap	65.08M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.686
ATR14	$0.0570 (5.33%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-08	Sigal Charles Elliott	Sell	45 453	Common Stock
2023-09-08	Sigal Charles Elliott	Sell	113 636	Stock Option (Right to Buy)
2023-09-08	Adams Chandra	Sell	23 884	Common Stock
2023-09-08	Adams Chandra	Sell	50 000	Stock Option (Right to Buy)
2023-09-08	Rath Henry C.	Sell	44 971	Common Stock

INSIDER POWER
-73.37
Last 94 transactions
Buy: 4 462 585 \| Sell: 5 534 482

Volume Correlation

Long: 0.03 (neutral)

Short: 0.31 (neutral)

Signal:(61.247) Neutral

Surface Oncology Inc Correlation

10 Most Positive Correlations
ISO	0.841
ARQT	0.833
ALLO	0.827
ALVR	0.818
DVAX	0.818
BGFV	0.816
ENNV	0.815
LQDT	0.805
ALZN	0.805
CARE	0.804

10 Most Negative Correlations
BNIXU	-0.817
USLB	-0.815

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Surface Oncology Inc Correlation - Currency/Commodity

0.80
( moderate )

0.73
( moderate )

0.00
( neutral )

0.77
( moderate )

-0.52
( weak negative )

-0.46
( neutral )

Surface Oncology Inc Financials

Annual	2022
Revenue:	$30.00M
Gross Profit:	$30.00M (100.00 %)
EPS:	$-1.170

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.460

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.340

Q4	2022
Revenue:	$30.00M
Gross Profit:	$30.00M (100.00 %)
EPS:	$-0.350

Financial Reports:

No articles found.

Surface Oncology Inc

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.